Abstract
Expression levels of the urokinase-type plasminogen activator receptor (uPAR) represent an established biomarker for poor prognosis in a variety of human cancers. The objective of the present study was to explore whether noninvasive PET can be used to perform a quantitative assessment of expression levels of uPAR across different human cancer xenograft models in mice and to illustrate the clinical potential of uPAR PET in future settings for individualized therapy.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of nuclear medicine : official publication, Society of Nuclear Medicine |
| Vol/bind | 53 |
| Udgave nummer | 1 |
| Sider (fra-til) | 138-45 |
| Antal sider | 8 |
| DOI | |
| Status | Udgivet - 2012 |